Frontline therapy for CLL, BTK inhibitors in CLL – ibrutinib/acalabrutinib, Novel combination therapy in CLL, MRD negativity in CLL and R/R CLL, Treatment sequencing & novel therapies
John Gribben, Susan O'Brien, Matthew Davids, Barbara Eichhorst
Already have an account? LOGIN HERE. If You don't have an account you need to create a free account.